Subsequently, the 28 selected drugs were further subjected to secondary screening, which involved a dose matrix of 6 × 8 in 5 human RCC cell lines (VHL WT: ACHN, CAKI-1, SN12C; VHL Null: 786-0 and 769-P), generating a further 6,720 dose-response signatures. Here, VHL is linked to renal cell carcinoma.